Zydus Lifesciences trades higher on getting orphan drug designation for ZYIL1 in treatment of patients with CAPS
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 478.75, up by 2.90 points or 0.61% from its previous closing of Rs. 475.85 on the BSE.
The scrip opened at Rs. 474.00 and has touched a high and low of Rs. 479.00 and Rs. 473.95 respectively. So far 7403 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 488.10 and Rs. 469.00 respectively. The current market cap of the company is Rs. 48216.34 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 16.21% and 8.81% respectively.
Zydus Lifesciences has been granted ‘Orphan Drug Designation’ (ODD) by the United States Food and Drug Administration (USFDA) for ZYIL1, for treatment of patients with Cryopyrin Associated Periodic Syndrome (CAPS). The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates. In September 2022, Zydus had announced positive Phase 2 proof-of-concept (POC) study in CAPS patients, and publication of Phase 1 study results in Clinical Pharmacology in Drug Development, supporting the advancement of ZYIL1 into pivotal clinical trials in CAPS patients.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
